Feasibility of the Maylard transverse incision for ovarian cancer cytoreductive surgery.
Title
Feasibility of the Maylard transverse incision for ovarian cancer cytoreductive surgery.
Creator
Fanning James; Pruett Allison; Flora Robert F
Publisher
Journal of minimally invasive gynecology
Date
2007
2007-06
Description
The vast majority of abdominal incisions used in gynecologic surgery are either transverse or vertical midline. The advantages of a vertical midline incision are considered to be rapid abdominal entry and increased exposure to the abdomen and pelvis. The advantages of transverse incisions are purported to be cosmesis, decreased postoperative pain, decreased hernia rate, decreased abdominal adhesions, and fewer postoperative pulmonary complications. The Maylard incision is a transverse incision that combines the advantages of a transverse incision with improved pelvic and abdominal exposure. We wanted to evaluate the feasibility of the Maylard incision to provide adequate abdominal and pelvic exposure in women with advanced ovarian cancer undergoing cytoreductive surgery and to evaluate the extent of anterior abdominal wall adhesions at secondary cytoreductive surgery. In our experience, it appears that the Maylard incision provides adequate exposure to perform ovarian cytoreductive surgery. It appears that there are minimal anterior abdominal adhesions after cytoreductive surgery through a Maylard incision.
Subject
80 and over; Aged; Feasibility Studies; Female; Gynecologic Surgical Procedures/adverse effects/*methods; Humans; Middle Aged; Ovarian Neoplasms/*surgery; Reoperation; Tissue Adhesions/*etiology
Identifier
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Citation
Fanning James; Pruett Allison; Flora Robert F, “Feasibility of the Maylard transverse incision for ovarian cancer cytoreductive surgery.,” NEOMED Bibliography Database, accessed June 6, 2023, https://neomed.omeka.net/items/show/3664.